Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA-HF: High-Dose Spironolactone in Acute Heart Failure
NCT02235077Phase 2Completed
- Sponsor
- Duke University
- Start
- Dec 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Acute Heart Failure (AHF) comparing High-Dose Spironolactone with Standard of Care / Placebo (2 arms). Primary endpoint: Change in NT-proBNP Levels at 96 hours. Started Dec 2014; status: completed.
02
Drugs
spironolactone
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT02235077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235077.